Jul 18, 2019
Regeneron Announces the 2019 Winners of the Regeneron Prize for Creative Innovation
Jun 28, 2019
CHMP Recommends Approval of Dupixent® (dupilumab) for Moderate-to-Severe Atopic Dermatitis in Adolescents
Jun 26, 2019
FDA Approves Dupixent® (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis
Jun 21, 2019
Regeneron and Sanofi Announce Positive Topline Phase 2 Results for IL-33 Antibody in Asthma
Jun 14, 2019
Regeneron CD20xCD3 Bispecific REGN1979 Shows Positive Results in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, including in CAR-T Failures
Jun 06, 2019
SillaJen Announces First Patient Enrolled in Part 2 of Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron's Libtayo® (cemiplimab-rwlc)
May 16, 2019
Updated Libtayo® (cemiplimab-rwlc) Results Reinforce Durable and Substantial Response Rates in Advanced Cutaneous Squamous Cell Carcinoma
May 15, 2019
Sanofi oncology pipeline targeting various cancers highlighted at ASCO 2019
May 13, 2019
FDA Approves EYLEA® (aflibercept) Injection for Diabetic Retinopathy
May 07, 2019
Regeneron Reports First Quarter 2019 Financial and Operating Results
May 07, 2019
Dupixent® (dupilumab) Approved for Severe Asthma by European Commission
Apr 29, 2019
Regeneron Announces Upcoming Investor Conference Presentations
Apr 12, 2019
FDA approves first targeted therapy for metastatic bladder cancer
Apr 08, 2019
Regeneron to Report First Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on May 7, 2019
Apr 08, 2019
Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases
Mar 15, 2019
Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
Mar 11, 2019
New Genetic Data from Regeneron and GSK on 50,000 UK Biobank Participants Made Available to Global Health Research Community
Mar 11, 2019
FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents
Mar 08, 2019
Regeneron Announces Upcoming Investor Conference Call
Mar 08, 2019
FDA to Undertake Priority Review of Dupixent® (dupilumab) for Adults with Inadequately Controlled Severe Chronic Rhinosinusitis with Nasal Polyps